88 related articles for article (PubMed ID: 21721201)
1. [Melanoma: a new therapeutic era].
Berthod G; Homicsko K; Bouchaab H; Matter M; Cerottini JP; Guggisberg D; Speiser D; Leyvraz S; Michielin O
Rev Med Suisse; 2011 May; 7(296):1126-30. PubMed ID: 21721201
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment strategies for malignant melanoma: a new beginning?
Kasper B; D'Hondt V; Vereecken P; Awada A
Crit Rev Oncol Hematol; 2007 Apr; 62(1):16-22. PubMed ID: 17208006
[TBL] [Abstract][Full Text] [Related]
3. The era of targeted therapies: increasing role for novel oncologic drugs in dermatology.
Montella L; Palmieri G; Lacouture M
Arch Dermatol; 2007 Jun; 143(6):788-9. PubMed ID: 17576948
[No Abstract] [Full Text] [Related]
4. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
5. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
6. Metastatic melanoma: the new era of targeted therapy.
Guida M; Pisconti S; Colucci G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S61-70. PubMed ID: 22443134
[TBL] [Abstract][Full Text] [Related]
7. Melanoma vaccines: possible progress after years of frustration?
Schmidt C
J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
[No Abstract] [Full Text] [Related]
8. Novel agents in acute myeloid leukemia.
Aribi A; Ravandi F; Giles F
Cancer J; 2006; 12(2):77-91. PubMed ID: 16630396
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment of metastatic melanoma: new approaches.
Hamid O; Boasberg PD; Rosenthal K; O'Day SJ
J Surg Oncol; 2011 Sep; 104(4):425-9. PubMed ID: 21858838
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in melanoma.
Queirolo P; Acquati M
Cancer Treat Rev; 2006 Nov; 32(7):524-31. PubMed ID: 17008014
[TBL] [Abstract][Full Text] [Related]
11. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
Agarwala SS
Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
[TBL] [Abstract][Full Text] [Related]
12. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
13. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies: a nursing perspective.
Kay P
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients.
Weber JS
Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797
[No Abstract] [Full Text] [Related]
16. [Are immunological treatments beneficial for malignant melanoma of the skin?].
Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic options in the medical management of advanced melanoma.
Lutzky J
Semin Cutan Med Surg; 2010 Dec; 29(4):249-57. PubMed ID: 21277538
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
19. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
20. [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].
Campone M; Kerbrat P; Roché H; Bennouna J; Cuillière JC; Le Mevel B; Fumoleau P
Bull Cancer; 2003 Oct; 90(10):851-64. PubMed ID: 14706914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
